
https://www.science.org/content/blog-post/no-easy-road-getting-rid-pains
# No Easy Road to Getting Rid of PAINS (February 2017)

## 1. SUMMARY

The article discusses a warning from UNC-Chapel Hill researchers about over-reliance on PAINs (pan-assay interference compounds) structural alerts to automatically deprioritize compounds in drug discovery. The researchers analyzed the PubChem database using software structural alerts for PAINs motifs and found that most flagged compounds did not actually show high AlphaScreen interference activity, and that PAINs alerts did not correlate with greater activity in other assay techniques either.

The article points out that some marketed drugs themselves trigger the same PAINs alerts, and similar percentages of "dark chemical matter" compounds (those that don't hit in any assays) also set off these software warnings. The author, Derek Lowe, acknowledges that while true interfering compounds exist—with quinones being the worst offenders—the approach of using long lists of substructure alerts has poor signal-to-noise beyond a few well-established problematic motifs. The conclusion emphasizes that orthogonal assays checking for aggregation, redox cycling, covalent reactivity, and fluorescence interference are essential, and that presence of top PAINs motifs should raise suspicion rather than trigger automatic dismissal.

## 2. HISTORY

Following the 2017 article, the discussion around PAINs has evolved significantly in drug discovery practice:

**Methodological Developments:** The field moved toward more sophisticated approaches combining computational filtering with experimental validation. Rather than purely algorithmic rejection, best practices now emphasize using PAINs alerts as risk flags requiring orthogonal assay confirmation. Several major pharmaceutical companies and academic screening centers published updated screening protocols that incorporate PAINs awareness without wholesale compound rejection.

**Community-Wide Efforts:** While the article called for community-wide screening efforts of PAINs alerts against multiple targets, systematic large-scale validation studies remained limited. However, the ChEMBL and PubChem databases continued to accumulate data that researchers used to refine PAINs filters and develop more target-specific interference patterns.

**Impact on Drug Discovery Practice:** The balanced approach advocated in the article became more widely adopted—screening libraries implemented smarter filtering that flagged suspicious compounds for additional testing rather than automatic exclusion. This reduced both false negative and false positive rates in early drug discovery campaigns.

**Academic vs. Industry Adoption:** Academic screening centers initially struggled more with PAINs-related issues due to less rigorous triage processes, but improved education and better assay design gradually mitigated these problems. Industry continued to refine their approaches, with many companies developing proprietary interference assays.

## 3. PREDICTIONS

• **Prediction:** The article called for "community-wide effort to screen and analyze a large set of commercially available compounds representing all current PAINs alerts against multiple targets in various assays was performed by several independent groups."

**Actual Outcome:** Limited progress. While some individual research groups published targeted validation studies, no comprehensive, coordinated community-wide screening effort materialized. Most validation remained fragmented across different research programs.

• **Prediction:** The author suggested that "rhodanine quinone should not be allowed to proceed without showing its papers, but lesser offenders should certainly be given a chance to prove themselves."

**Actual Outcome:** This graduated approach became standard practice. Major compound vendors and screening facilities implemented tiered risk assessment systems where high-risk PAINs motifs (like quinones) require extensive validation before proceeding, while moderate-risk compounds receive standard orthogonal testing.

• **Prediction:** Implicit prediction that "assay data, real assay data, is the only way to be sure" would remain the gold standard.

**Actual Outcome:** Confirmed and reinforced. The pharmaceutical industry increasingly invested in comprehensive assay cascades and counter-screening panels to identify interference mechanisms early. Computational approaches remained supplementary rather than replacement for experimental validation.

• **Prediction:** The warning against "blast through a list of compounds crossing things off automatically with no further evidence" being "wrong."

**Actual Outcome:** The field largely moved away from purely computational triage. Best practices converged on using PAINs filters as risk assessment tools that trigger additional experimental investigation rather than automatic deprioritization.

## 4. INTEREST

Rating: **6/10**

The article addresses an important technical challenge in drug discovery that affects both academic and industrial research, contributing to better experimental design practices in the years following its publication.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20170207-no-easy-road-getting-rid-pains.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_